TrueBlue FY 2025 earnings snapshot

TrueBlue (TBI) has capped FY 2025 with fourth quarter revenue of US$418.2 million and a basic EPS loss of US$1.05. On a trailing twelve month view, revenue sits at about US$1.6 billion and EPS is a loss of US$1.61. Over recent quarters the company has reported revenue of US$382.4 million in Q3 2024 and US$418.2 million in Q4 2025, while quarterly EPS has ranged from a loss of US$0.26 in Q3 2024 to a loss of US$1.05 in Q4 2025. Margins remain under pressure, so a key consideration for investors is whether any future improvement in performance could be sufficient to absorb these losses.

See our full analysis for TrueBlue.

With the headline numbers set, the next step is to see how TrueBlue's results align with the widely followed turnaround narrative and where the data may challenge existing views.

Losses widen again in Q4

• TrueBlue reported a net loss of US$31.5 million in Q4 2025 and a trailing twelve month loss of US$48.0 million, compared with quarterly losses that were as small as US$0.16 million earlier in FY 2025.
• Bears point out that losses have widened at about 39.2% per year over the past five years, and the latest Q4 loss lines up with that concern. At the same time, revenue over the last year is reported as growing around 4.4% per year, which is below the cited 11.2% US market growth rate.
  • This combination of a US$1.6b trailing revenue base and ongoing losses supports the bearish view that lower margin work and cost pressures are still weighing on profitability even as sales grind higher.
  • The fact that quarterly losses earlier in FY 2025 were much smaller than Q4 challenges a simple straight line bearish story and suggests results can move around from one period to the next.

Skeptics who focus on the widening loss trend may want to see how that argument stacks up against the full bear case narrative for TrueBlue before drawing conclusions. 🐻 TrueBlue Bear Case

Revenue growth steady but behind market

• On a trailing basis TrueBlue generated about US$1.6b of revenue, with the analysis data pointing to roughly 4.4% yearly revenue growth compared with the 11.2% figure cited for the broader US market.
• Analysts with a more balanced view highlight that demand in areas like energy, health care and skilled roles could support future growth. However, the current 4.4% revenue growth rate and negative net margin show that these tailwinds have not yet translated into higher profitability.
  • The consensus narrative expects revenue to reach about US$1.8b by around 2028, which is only modestly above the current trailing level and relies on a move from a trailing net loss of US$48.0 million to positive earnings.
  • Because the present growth rate is slower than the US market, this consensus stance leans on the assumption that mix shift and cost discipline will matter more than raw top line acceleration.

Deep discount to DCF fair value

• The stock trades at a P/S of about 0.1x and a share price of US$6.04, while the provided DCF fair value is US$77.25, and analysts in the summary reference an average price target of US$7.75.
• Bullish investors argue that this wide gap, combined with forecasts for earnings to grow about 148.92% per year and a path to profitability within three years, supports a recovery case. Current trailing data still shows a US$48.0 million loss and slower 4.4% revenue growth, so the numbers also test how much weight to put on those future estimates.
  • The contrast between a 0.1x P/S multiple and higher industry and peer averages, alongside the DCF fair value of US$77.25, is part of why bulls see the current price as heavily discounted.
  • The requirement for earnings to swing from a loss of US$28.1 million in the trailing analysis reference to positive earnings figures by the late 2020s underlines how dependent that bullish case is on the forecast improvement actually occurring.

If you want to see how those bullish expectations link back to detailed earnings forecasts, margin assumptions and revenue mix, the full bull narrative helps set out that case in one place. 🐂 TrueBlue Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for TrueBlue on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the numbers and narratives so far? Take a closer look at the data now and shape your own view with 3 key rewards and 1 important warning sign

See What Else Is Out There

TrueBlue is operating with trailing revenue of about US$1.6 billion and a loss of approximately US$48.0 million, along with revenue growth that lags the broader US market.

If those pressure points around profitability and slower growth concern you, you may wish to compare them with companies in the 74 resilient stocks with low risk scores to focus on stocks with relatively stronger risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.